Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript

SA Transcripts 161.47K Followers Follow Palvella Therapeutics, Inc. ( PVLA ) Q2 2026 Earnings Call August 4, 2026 8:30 AM EDT Company Participants Marcy Nanus Wesley Kaupinen - Founder, President, CEO & Director Jeffrey Martini - Chief Scientific Officer Matthew Korenberg - CFO, Corporate Secretary & Treasurer Conference Call Participants Alexa Deemer - Cantor Fitzgerald & Co., Research Division Whitney Ijem - Canaccord Genuity Corp., Research Division Ritu Baral - TD Cowen, Research Division Annabel Samimy - Stifel, Nicolaus & Company, Incorporated, Research Division Ryan Ries - Mizuho Securities USA LLC, Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Samuel Slutsky - LifeSci Capital, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Palvella Therapeutics' Second Quarter 2026 Financial Results Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Marcy Nanus, Vice President of Investor Relations and Corporate Affairs. Marcy Nanus Thank you, operator. Good morning, and thank you for joining the Palvella Therapeutics' second quarter 2026 Financial Results And Corporate Update Call. As a reminder, our press release detailing today's announcements can be found in the Investors section of our website at www.palvellatx.com. On today's call, I am joined by Wes Kaupinen, our Founder and Chief Executive Officer; Dr. Jeff Martini, our Chief Scientific Officer; and Matt Korenberg, our Chief Financial Officer. Before we begin, please note that today's remarks may include forward-looking statements regarding our development programs, regulatory strategy, commercial planning and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors. And now I'll turn the call over to Wes. Wesley Kaupinen